| Entry |
|
|---|
| Name |
Oxcarbazepine (JAN/USP/INN);
Oxtellar (TN);
Trileptal (TN) |
|---|
| Product |
|
|---|
| Generic |
OXCARBAZEPINE (American Health Packaging), OXCARBAZEPINE (Amneal Pharmaceuticals LLC), OXCARBAZEPINE (Breckenridge Pharmaceutical), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Bryant Ranch Prepack), OXCARBAZEPINE (Cardinal Health), OXCARBAZEPINE (Glenmark Pharmaceuticals), OXCARBAZEPINE (Golden State Medical Supply), OXCARBAZEPINE (NCS HealthCare of KY), OXCARBAZEPINE (Precision Dose), OXCARBAZEPINE (Proficient Rx LP), OXCARBAZEPINE (Quality Care Products), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (REMEDYREPACK), OXCARBAZEPINE (Sandoz), OXCARBAZEPINE (Sun Pharmaceutical Industries), OXCARBAZEPINE (Taro Pharmaceuticals U.S.A.), OXCARBAZEPINE (West-Ward Pharmaceuticals Corp.) |
|---|
| Formula |
C15H12N2O2
|
|---|
| Exact mass |
252.0899
|
|---|
| Mol weight |
252.268
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG02034 Carboxamide antiepileptics
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
Metabolizing enzyme inducer
DG02853 CYP3A inducer
|
|---|
| Remark |
|
|---|
| Efficacy |
Anticonvulsant, Antiepileptic |
|---|
| Comment |
Carboxamide derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
CYP inhibition: CYP2C19 [HSA: 1557]
CYP induction: CYP3A [HSA: 1576 1577 1551]
|
|---|
| Structure map |
|
|---|
| Other map |
| map00982 | Drug metabolism - cytochrome P450 |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AF Carboxamide derivatives
N03AF02 Oxcarbazepine
D00533 Oxcarbazepine (JAN/USP/INN) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Oxcarbazepine
D00533 Oxcarbazepine (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN2A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN3A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN4A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN5A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN8A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN9A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN10A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
SCN11A
D00533 Oxcarbazepine (JAN/USP/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00533
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00533
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00533
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00533
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00533
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 19
1 C5x C 18.8052 -13.4873
2 C8y C 17.9608 -12.3747
3 C8y C 18.2969 -11.0142
4 N1y N 19.5614 -10.4345
5 C1x C 20.2148 -13.5126
6 C8y C 20.8183 -11.0585
7 C8y C 21.1056 -12.4310
8 C8x C 17.2870 -10.0431
9 C8x C 15.9414 -10.4323
10 C8x C 15.6053 -11.7928
11 C8x C 16.6151 -12.7636
12 C8x C 22.4404 -12.8693
13 C8x C 23.4875 -11.9323
14 C8x C 23.2004 -10.5598
15 C8x C 21.8653 -10.1215
16 C5a C 19.5131 -9.0558
17 N1a N 20.7404 -8.3728
18 O5x O 18.0836 -14.6869
19 O5a O 18.2961 -8.3686
BOND 21
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 2 11 2
13 7 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 6 15 2
18 4 16 1
19 16 17 1
20 1 18 2
21 16 19 2
|
|---|
